Nocturia – Pipeline Review, H1 2019 Featuring Ferring International Center, Sanwa Kagaku Kenkyusho Co, and Vantia – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nocturia
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Nocturia – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Nocturia (Genito Urinary System and Sex Hormones), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Nocturia (Genito Urinary System and Sex
Hormones) pipeline guide also reviews of key players involved in
therapeutic development for Nocturia and features dormant and
discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III and Phase II stages are 3 and 4 respectively.

Nocturia (Genito Urinary System and Sex Hormones) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Nocturia (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nocturia (Genito
    Urinary System And Sex Hormones) by companies and
    universities/research institutes based on information derived from
    company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Nocturia (Genito
    Urinary System And Sex Hormones) therapeutics and enlists all their
    major and minor projects.
  • The pipeline guide evaluates Nocturia (Genito Urinary System And Sex
    Hormones) therapeutics based on mechanism of action (MoA), drug
    target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Nocturia (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and
    focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Ferring International Center S.A.
  • Sanwa Kagaku Kenkyusho Co. Ltd.
  • Vantia Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5v5u92

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Urological
Disorders Drugs